Search

Displaying results 1891 - 1900 of 5263 in total
  1. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.[A252667] … [A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.

  2. Drug

    Laronidase

    go.drugbank.com/drugs/DB00090
    ApprovedInvestigational

    Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line. … It contains 6 N-linked oligosaccharide modification sites.

  3. Drug

    Vonicog alfa

    go.drugbank.com/drugs/DB12872
    ApprovedInvestigational

    Vonicog alfa is a recombinant human von Willebrand factor (rVWF) produced from Chinese hamster ovary cells.

  4. Drug

    Thiabendazole

    go.drugbank.com/drugs/DB00730
    ApprovedVet approvedWithdrawn

    (From Smith and Reynard, Textbook of Pharmacology, 1992, p919)

  5. Drug

    Sodium glycerophosphate

    go.drugbank.com/drugs/DB09561
    Approved

    Sodium glycerophosphate is one of several glycerophosphate salts. It is used clinically to treat or prevent low phosphate levels [FDA Label]. Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body . The extent of ...

    Mixtures: OLICLINOMEL N4-550 E EMULSION FOR INFUSION, OLICLINOMEL N7-1000 E EMULSION FOR INFUSION
  6. Drug

    Phenytoin

    go.drugbank.com/drugs/DB00252
    ApprovedInvestigationalVet approved

    [A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications … [A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal

  7. Drug

    Gadodiamide

    go.drugbank.com/drugs/DB00225
    ApprovedInvestigational

    [A263096] Approved by the FDA in 1993, gadodiamide is the first non-ionic GBCA to be used.

  8. Drug

    Thymalfasin

    go.drugbank.com/drugs/DB04900
    Investigational

    Thymalfasin is a chemically synthesized version of thymosin alpha 1 that is identical to human thymosin alpha 1. Thymosin alpha 1 is an acetylated polypeptide. Thymosin alpha 1 is now approved in 35 developing countries for the treatment...

  9. Drug

    Dithiazanine

    go.drugbank.com/drugs/DB11516
    ApprovedVet approvedWithdrawn

    Dithiazanine iodide has been withdrawn from the market in countries such as France in Italy, but it may remain available in others.[A254427,L44032]

  10. Drug

    Pipradrol

    go.drugbank.com/drugs/DB11584
    ApprovedWithdrawn

    Pipradrol (Meratran) was initially developed in the 1950s as an antidepressant, however, the adverse effects associated with its use and its abuse potential led to its withdrawal and international regulation . Pipradrol was made illegal ...